NICE reconsiders and agrees to back Roche’s Ocrevus in relapsing multiple sclerosis—with strings attached
admin 22nd June 2018 Uncategorised 0About two months after England’s cost watchdog decided Roche’s multiple sclerosis star Ocrevus wasn’t cost-effective enough to win reimbursement backing in relapsing forms of the disease, the agency overturned that ruling with one limitation.
More: NICE reconsiders and agrees to back Roche’s Ocrevus in relapsing multiple sclerosis—with strings attached
Source: fierce